Novartis Diovan Gets Heart Failure Claim But Is Second Line To ACE Inhibitors

Novartis' Diovan approval for the treatment of heart failure makes the drug the first angiotensin II receptor blocker to carry the indication, but limits it to patients who cannot take ACE inhibitors